A pharmaceutical emulsion is a liquid disperse system that has the dispersed phase made of small globules of a liquid distributed evenly throughout a vehicle in which the dispersed phase is immiscible. The dispersed phase is the internal or discontinuous phase and the dispersion medium is the external or continuous phase. The diameter of the dispersed phase globules in the range of 0.1 to 10 micrometers. However, it can be as large as 100 micrometers or as small as 0.01 micrometers. Pharmaceutical emulsions include lotions of relatively low viscosity, creams that are semisolid in nature, and ointments.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
However, with COVID-19 the supply chain of raw materials required to manufacture pharmaceutical emulsions has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining, as manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the pharmaceutical emulsion market.
Top Impacting Factors
The number of cases of dry skin conditions such as ichthyosis, eczema, and pruritus of the elderly is increasing all across the world. These conditions often require the use of creams that contain liquid paraffin in the form of an emulsion. Therefore, this factor is boosting the growth of the pharmaceutical emulsion market.
In addition, many patients are being admitted to hospitals these days who suffer from abnormal vitamin levels requiring total parenteral nutrition. In such cases, healthcare providers often use parenteral vitamins in emulsion form. This has further led to the market growth of pharmaceutical emulsions.
External emulsions such as creams are used in preparing a variety of cosmetic products. In addition, rise in the number of people focused on their external experience and beauty has boosted the growth of the pharmaceutical emulsion market.
However, increase in regulatory stringency regarding the approval of pharmaceutical emulsions acts as a restraining factor of the pharmaceutical emulsion market.
Key Market Trends
The use of rectal emulsions has increased in recent years, as they are used in enemas. Rectal emulsions are liquid preparations that are used for rectal application. These emulsions offer a systemic or local effect on the body. They may be intended for diagnostic purposes.
The segment of topically applied emulsions is expected to increase during the forecast period. This can be attributed to the control that these emulsions offer over their viscosity and degree of greasiness while manufacturing dermatologic and cosmetic products.
Rising number of cases of severe constipation is further anticipated to lead to the growth of the pharmaceutical emulsion market. This is attributable to the fact that many laxatives are often prepared in the form of emulsions, which make them more palatable.
Key players of the pharmaceutical emulsion market are focusing on strategies such as mergers, acquisitions, and collaborations, which are expected to help them serve a larger customer base globally.
Key Benefits of the Report
- This study presents the analytical depiction of the pharmaceutical emulsion industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Pharmaceutical Emulsion Report
- Which are the leading players active in the pharmaceutical emulsion market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the pharmaceutical emulsion market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
- What are the impacts of COVID-19 on the industry?
- What is a pharmaceutical emulsion?
- What are the current and predicted trends of the market?
Pharmaceutical Emulsion Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Particle Size |
|
 By Mode of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Merck and Co., Inc., Alkermes PLC, Omeros Corporation, Indivior PLC, Johnson and Johnson, Inc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd, Bayer AG, Inc., Novartis AG, F. Hoffman-La Roche |
Loading Table Of Content...
